3 Reasons to Buy CRISPR Therapeutics Stock
The company's innovative qualities may pay rich dividends down the road.
Overview
CRISPR Therapeutics (NASDAQ: CRSP) has significantly underperformed broader equities over the past five years. Some will argue the company's value -- its market cap is $5.7 billion as of writing -- is still too high given the fundamentals of the business. CRISPR Therapeutics generates little revenue, is consistently unprofitable, and hasn't earned significant late-stage clinical wins over the past couple of years. However, despite all that, CRISPR Therapeutics could be an attractive buy-and-hold option. Let's consider three reasons why the biotech is worth serious consideration.
CRISPR Therapeutics specializes in developing gene editing therapies. This technology has already helped unlock groundbreaking medicines for otherwise difficult-to-treat conditions. However, we are arguably still in the early innings of the gene-editing revolution in the biotech industry, as the U.S. Food and Drug Administration has approved only a few treatments of this kind. But thanks to its potential to transform standards of care across many therapeutic areas, it's worth investors' time to look for the best gene-editing-focused companies. CRISPR Therapeutics fits the bill.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.